Proteomics technologies for cancer liquid biopsies

• Published in: Molecular cancer Vol. 21; no. 1; pp. 53 - 11
• Main Authors: Ding, Zhiyong, Wang, Nan, Ji, Ning, Chen, Zhe-Sheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.02.2022; BioMed Central; BMC
• Subjects: Acids; Analysis; Antibodies; Antigens; Aptamer; Aptamers; Biomarkers; Biopsy; Body fluids; Cancer; Cancer liquid biopsy; Clinical medicine; Development and progression; Early Detection of Cancer; Epigenetics; Genomes; Humans; Immunoassay; Liquid Biopsy; Mass spectrometry; Mass spectrometry (MS); Mass spectroscopy; Medical screening; Neoplasms - diagnosis; Neoplasms - genetics; Ovarian cancer; Peptides; Plasma; Prostate; Protein arrays; Proteins; Proteome - metabolism; Proteomes; Proteomics; Proteomics - methods; Proximity extension assay (PEA); Reverse phase protein arrays (RPPA); Review; Scientific imaging; Therapeutic applications; Urine; Viral antibodies; Reverse phase protein arrays (RPPA); Antibody arrays; Cancer liquid biopsy; Proximity extension assay (PEA); Mass spectrometry (MS); Proteomics; Aptamer
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-022-01526-8

Alterations in DNAs could not reveal what happened in proteins. The accumulated alterations of DNAs would change the manifestation of proteins. Therefore, as is the case in cancer liquid biopsies, deep proteome profiling will likely provide invaluable and clinically relevant information in real-time throughout all stages of cancer progression. However, due to the great complexity of proteomes in liquid biopsy samples and the limitations of proteomic technologies compared to high-plex sequencing technologies, proteomic discoveries have yet lagged behind their counterpart, genomic technologies. Therefore, novel protein technologies are in urgent demand to fulfill the goals set out for biomarker discovery in cancer liquid biopsies. Notably, conventional and innovative technologies are being rapidly developed for proteomic analysis in cancer liquid biopsies. These advances have greatly facilitated early detection, diagnosis, prognosis, and monitoring of cancer evolution, adapted or adopted in response to therapeutic interventions. In this paper, we review the high-plex proteomics technologies that are capable of measuring at least hundreds of proteins simultaneously from liquid biopsy samples, ranging from traditional technologies based on mass spectrometry (MS) and antibody/antigen arrays to innovative technologies based on aptamer, proximity extension assay (PEA), and reverse phase protein arrays (RPPA).